Medscape

FDA Approves Subcutaneous Infliximab for IBD

The US Food and Drug Administration (FDA) has approved infliximab-dyyb (Zymfentra, Celltrion USA) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn ...
Healio

Second anti-TNF ‘reasonable option’ for UC, whether infliximab or subcutaneous agent

Please provide your email address to receive an email when new articles are posted on . Use of a second anti-TNF — IV or subcutaneous agent — resulted in early response and long-term remission among ...
Business Wire

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease

The latest clinical trial data for subcutaneous (SC) infliximab (CT-P13 SC), presented at the United European Gastroenterology (UEG) Week 2023 in Copenhagen, further support the potential of CT-P13 SC ...
Business Wire

Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...